FI953378A0 - Sytokiiniä pidättävät aineet - Google Patents

Sytokiiniä pidättävät aineet

Info

Publication number
FI953378A0
FI953378A0 FI953378A FI953378A FI953378A0 FI 953378 A0 FI953378 A0 FI 953378A0 FI 953378 A FI953378 A FI 953378A FI 953378 A FI953378 A FI 953378A FI 953378 A0 FI953378 A0 FI 953378A0
Authority
FI
Finland
Prior art keywords
cytokine
withholding
substances
subject
provides
Prior art date
Application number
FI953378A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI953378A (fi
Inventor
Mark J Suto
Beverly E Girten
Richard A Houghten
Costas C Loullis
Ronald R Tuttle
Original Assignee
Houghten Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Houghten Pharm Inc filed Critical Houghten Pharm Inc
Publication of FI953378A0 publication Critical patent/FI953378A0/fi
Publication of FI953378A publication Critical patent/FI953378A/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • C07K14/68—Melanocyte-stimulating hormone [MSH]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • C07K14/68—Melanocyte-stimulating hormone [MSH]
    • C07K14/685—Alpha-melanotropin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • C07K14/695—Corticotropin [ACTH]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic
FI953378A 1993-11-12 1995-07-10 Sytokiiniä pidättävät aineet FI953378A (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/151,534 US5420109A (en) 1993-11-12 1993-11-12 Cytokine restraining agents
PCT/US1994/012897 WO1995013086A1 (en) 1993-11-12 1994-11-09 Cytokine restraining agents

Publications (2)

Publication Number Publication Date
FI953378A0 true FI953378A0 (fi) 1995-07-10
FI953378A FI953378A (fi) 1995-07-10

Family

ID=22539190

Family Applications (1)

Application Number Title Priority Date Filing Date
FI953378A FI953378A (fi) 1993-11-12 1995-07-10 Sytokiiniä pidättävät aineet

Country Status (14)

Country Link
US (3) US5420109A (de)
EP (1) EP0679092B1 (de)
JP (2) JP2793719B2 (de)
KR (1) KR100248033B1 (de)
AT (1) ATE179429T1 (de)
CA (1) CA2153584C (de)
DE (1) DE69418181T2 (de)
DK (1) DK0679092T3 (de)
ES (1) ES2130574T3 (de)
FI (1) FI953378A (de)
GR (1) GR3030382T3 (de)
NO (1) NO952744L (de)
NZ (1) NZ276906A (de)
WO (1) WO1995013086A1 (de)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5786332A (en) * 1995-03-06 1998-07-28 Trega Biosciences, Inc. Cytokine restraining agents and methods of use in pathologies and conditions associated with altered cytokine levels
US5420109A (en) * 1993-11-12 1995-05-30 Houghten Pharmaceuticals, Inc. Cytokine restraining agents
US5726156A (en) * 1995-03-06 1998-03-10 Trega Biosciences, Inc. Cytokine regulatory agents and methods of use in pathologies and conditions associated with altered cytokine levels
US5741774A (en) * 1993-11-12 1998-04-21 Trega Biosciences, Inc. Use of a cytokine regulatory agent to treat rheumatoid arthritis
KR970706835A (ko) * 1995-09-12 1997-12-01 버나드 디. 킹 위장 손상의 심각도의 감소 방법(Method for Reducing The Severity of Gastro-Intestinal Damage)
IL130238A0 (en) * 1999-06-01 2000-06-01 Peptor Ltd Conformationally constrained backbone cyclized interleukin-6 antagonists
US6841533B1 (en) 1995-12-07 2005-01-11 Peptor Limited Conformationally constrained backbone cyclized interleukin-6 antagonists
US6045788A (en) * 1996-02-28 2000-04-04 Cornell Research Foundation, Inc. Method of stimulation of immune response with low doses of IL-2
US6509313B1 (en) * 1996-02-28 2003-01-21 Cornell Research Foundation, Inc. Stimulation of immune response with low doses of cytokines
AU4491697A (en) * 1996-09-27 1998-04-17 Trega Biosciences, Inc. Compositions of therapeutic agents suitable for oral administration
US20020159995A1 (en) * 1997-07-30 2002-10-31 Renal Tech International Devices, systems, and methods for reducing levels of pro-inflammatory or anti-inflammatory stimulators or mediators in the blood, generated as a result of extracorporeal blood processing
US20020197250A1 (en) * 2001-04-10 2002-12-26 Renal Tech International Biocompatible devices, systems, and methods for reducing levels of pro-inflammatory or anti-inflammatory stimulators or mediators in the blood
US20020198487A1 (en) * 2001-04-10 2002-12-26 Renal Tech International Devices, systems, and methods for reducing levels of pro-inflammatory or anti-inflammatory stimulators or mediators in physiologic fluids
US20020197249A1 (en) * 2001-04-10 2002-12-26 Renal Tech International Devices, systems, and methods for reducing levels of pro-inflammatory or anti-inflammatory stimulators or mediators in blood products
US8329388B2 (en) * 1997-07-30 2012-12-11 Cytosorbents, Inc. Biocompatible devices, systems, and methods for reducing levels of proinflammatory of antiinflammatory stimulators or mediators in the blood
AU7464998A (en) 1997-10-27 1999-05-17 Trega Biosciences, Inc. Melanocortin receptor ligands and methods of using same
EP1074268B1 (de) * 1998-03-17 2008-01-16 Chugai Seiyaku Kabushiki Kaisha Prophylaktische oder therapeutische mittel gegen entzündliche erkrankungen des verdauungstraktes enthaltend antagonistische il-6 rezeptor antikörper
US6284735B1 (en) 1998-04-28 2001-09-04 Lion Bioscience Ag HP-3228 and related peptides to treat sexual dysfunction
EP1076649A4 (de) 1998-04-28 2010-06-02 Trega Biosciences Inc Isoquinolinverbindung, melanocortinrezeptor-liganden und anwendungsverfahren derselben
US6534503B1 (en) 1998-04-28 2003-03-18 Lion Bioscience Ag Melanocortin receptor-3 ligands to treat sexual dysfunction
US6716810B1 (en) * 1998-12-09 2004-04-06 Eleanor Roosevelt Institute Composition and method for regulation of body weight and associated conditions
US6579968B1 (en) * 1999-06-29 2003-06-17 Palatin Technologies, Inc. Compositions and methods for treatment of sexual dysfunction
US7176279B2 (en) * 2000-06-28 2007-02-13 Palatin Technologies, Inc. Cyclic peptide compositions and methods for treatment of sexual dysfunction
EP1593384A3 (de) * 1999-06-29 2006-04-26 Palatin Technologies, Inc. Verbindungen zur Behandlung von sexuellen Funktionsstörungen
AU6605800A (en) * 1999-07-16 2001-02-05 Trega Biosciences, Inc. Melanocortin receptor-3 ligands to treat sexual dysfunction
US6921530B1 (en) 1999-09-24 2005-07-26 Cornell Research Foundation, Inc. Low dose IL-2 for potentiation of immunity
US6358939B1 (en) 1999-12-21 2002-03-19 Northern Lights Pharmaceuticals, Llc Use of biologically active vitamin D compounds for the prevention and treatment of inflammatory bowel disease
US6989377B2 (en) 1999-12-21 2006-01-24 Wisconsin Alumni Research Foundation Treating vitamin D responsive diseases
US6878127B2 (en) 2001-04-10 2005-04-12 Renaltech International, Llc Devices, systems, and methods for reducing levels of pro-inflammatory or anti-inflammatory stimulators or mediators in the blood
US8703146B2 (en) * 2001-04-20 2014-04-22 Institute For Systems Biology Toll-like receptor 5 ligands and methods of use
EP1379552B2 (de) * 2001-04-20 2014-11-19 The Institute for Systems Biology Toll-ähnlichen-rezeptor-5-liganden und verwendungsverfahren
IL159797A0 (en) * 2001-07-11 2004-06-20 Palatin Technologies Inc Linear and cyclic melanocortin receptor-specific peptides
US7034004B2 (en) 2002-05-07 2006-04-25 University Of Florida Peptides and methods for the control of obesity
US7067621B2 (en) * 2002-08-20 2006-06-27 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Multifunctional context-activated protides and methods of use
WO2004017727A1 (en) * 2002-08-23 2004-03-04 The Walter And Eliza Hall Institute Of Medical Research A method of treatment and prophylaxis
AU2002950957A0 (en) * 2002-08-23 2002-09-12 The Walter And Eliza Hall Institute Of Medical Research A method of treatment and prophylaxis
US6974187B2 (en) * 2004-01-28 2005-12-13 Tachi-S Co., Ltd. Vehicle seat structure
FR2869531B1 (fr) * 2004-04-30 2006-07-14 Optis France Sa Sa Dispositif de iontophorese oculaire diminuant les irritations
EP1758598B1 (de) * 2004-04-30 2016-04-13 Eyegate Pharma SAS Irritationsvermindernde iontophoresevorrichtung für das auge
US20060270707A1 (en) * 2005-05-24 2006-11-30 Zeldis Jerome B Methods and compositions using 4-[(cyclopropanecarbonylamino)methyl]-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione for the treatment or prevention of cutaneous lupus
TWI334784B (en) * 2006-04-14 2010-12-21 Buck Inst For Age Res Compositions and methods for suppression of amyloid plaque formation associated with neurodegenerative disorders
WO2010042933A2 (en) 2008-10-10 2010-04-15 Northwestern University Inhibition and treatment of prostate cancer metastasis
ES2679673T3 (es) 2008-12-31 2018-08-30 Eyegate Pharmaceuticals, Inc. Sistema para iontoforesis ocular con amortiguación
AU2011248625B2 (en) 2010-04-26 2017-01-05 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of cysteinyl-tRNA synthetase
JP6294074B2 (ja) 2010-04-27 2018-03-14 エータイアー ファーマ， インコーポレイテッド イソロイシルｔＲＮＡ合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
CA2797271C (en) 2010-04-28 2021-05-25 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of alanyl trna synthetases
CA2797393C (en) 2010-04-29 2020-03-10 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of valyl trna synthetases
CN103097523B (zh) 2010-04-29 2016-09-28 Atyr医药公司 与天冬酰胺酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现
CN103096925A (zh) 2010-05-03 2013-05-08 Atyr医药公司 与精氨酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现
AU2011248227B2 (en) 2010-05-03 2016-12-01 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-alpha-tRNA synthetases
ES2668207T3 (es) 2010-05-03 2018-05-17 Atyr Pharma, Inc. Descubrimiento innovador de composiciones terapéuticas, de diagnóstico y de anticuerpos relacionadas con fragmentos de proteínas de metionil-ARNt sintetasas
CN102985103A (zh) 2010-05-04 2013-03-20 Atyr医药公司 与p38多-tRNA合成酶复合物相关的治疗、诊断和抗体组合物的创新发现
US8945541B2 (en) 2010-05-14 2015-02-03 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-beta-tRNA synthetases
CA2799480C (en) 2010-05-17 2020-12-15 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of leucyl-trna synthetases
EP2575856B1 (de) 2010-05-27 2017-08-16 aTyr Pharma, Inc. Therapeutische, diagnostische und antikörperhaltige zusammensetzungen in zusammenhang mit proteinfragmenten von glutaminyl-trna-synthetasen
EP2575857B1 (de) 2010-06-01 2018-01-24 aTyr Pharma, Inc. Innovative erkennung therapeutischer, diagnostischer und antikörperhaltiger zusammensetzungen in zusammenhang mit proteinfragmenten von lysyl-trna-synthetasen
WO2012021247A2 (en) 2010-07-12 2012-02-16 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glycyl-trna synthetases
CA2808539C (en) 2010-08-25 2021-05-25 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of tyrosyl-trna synthetases
US8835387B2 (en) 2012-02-16 2014-09-16 Atyr Pharma, Inc. Histidyl-tRNA synthetases for treating autoimmune and inflammatory diseases
ES2708565T3 (es) 2013-03-15 2019-04-10 Atyr Pharma Inc Conjugados de Fc-histidil-ARNt sintetasa
US9839625B2 (en) 2014-11-06 2017-12-12 Northwestern University Inhibition of cancer cell motility
WO2018195338A1 (en) 2017-04-20 2018-10-25 Atyr Pharma, Inc. Compositions and methods for treating lung inflammation

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4457864A (en) * 1981-10-23 1984-07-03 University Patents, Inc. Synthetic analogues of α-melanotropin
US4485039A (en) * 1982-06-11 1984-11-27 University Patents, Inc. Synthetic analogues of α-melanotropin
US4649191A (en) * 1984-05-10 1987-03-10 Gibson-Stephens Neuropharmaceuticals, Inc. Conformationally constrained alpha-melanotropin analogs with specific central nervous system activity
US5028592A (en) * 1986-08-08 1991-07-02 Lipton James M Antipyretic and anti-inflammatory peptides
US5157023A (en) * 1984-08-21 1992-10-20 Lipton James M Antipyretic and anti-inflammatory lys pro val compositions and method of use
ATE84420T1 (de) * 1986-02-03 1993-01-15 University Patents Inc Verfahren zur stimulierung von melanozyten durch lokales anbringen von alpha-msh-analogen, sowie zusammensetzungen.
ATE109793T1 (de) * 1987-05-22 1994-08-15 University Patents Inc Lineare und zyklische analoge von alpha-msh- fragmenten mit ausserordentlicher wirkung.
JP2711549B2 (ja) * 1987-06-01 1998-02-10 圭吉 杉山 白髪防止・改善用組成物
US5049547A (en) * 1988-02-11 1991-09-17 University Patents, Inc. Composition for stimulating integumental melanocytes
US5114960A (en) * 1989-07-20 1992-05-19 Hoffmann-La Roche Inc. Substituted isoxazole derivatives
ZA908610B (en) * 1989-11-03 1991-08-28 Univ Tulane Peptides aiding nerve regeneration
IL101769A (en) * 1992-05-03 2007-02-11 Yeda Res & Dev Modulation of TNF receptor action
US5786332A (en) * 1995-03-06 1998-07-28 Trega Biosciences, Inc. Cytokine restraining agents and methods of use in pathologies and conditions associated with altered cytokine levels
US5420109A (en) * 1993-11-12 1995-05-30 Houghten Pharmaceuticals, Inc. Cytokine restraining agents
US5741774A (en) * 1993-11-12 1998-04-21 Trega Biosciences, Inc. Use of a cytokine regulatory agent to treat rheumatoid arthritis
US5726156A (en) * 1995-03-06 1998-03-10 Trega Biosciences, Inc. Cytokine regulatory agents and methods of use in pathologies and conditions associated with altered cytokine levels

Also Published As

Publication number Publication date
EP0679092B1 (de) 1999-04-28
JPH10259196A (ja) 1998-09-29
NO952744D0 (no) 1995-07-11
EP0679092A1 (de) 1995-11-02
NO952744L (no) 1995-09-08
US5888969A (en) 1999-03-30
NZ276906A (en) 1997-05-26
ATE179429T1 (de) 1999-05-15
CA2153584A1 (en) 1995-05-18
EP0679092A4 (de) 1997-11-19
FI953378A (fi) 1995-07-10
DE69418181T2 (de) 1999-12-23
JP3357883B2 (ja) 2002-12-16
JP2793719B2 (ja) 1998-09-03
US6245738B1 (en) 2001-06-12
GR3030382T3 (en) 1999-09-30
DK0679092T3 (da) 1999-11-08
AU1174195A (en) 1995-05-29
AU678329B2 (en) 1997-05-22
DE69418181D1 (de) 1999-06-02
ES2130574T3 (es) 1999-07-01
WO1995013086A1 (en) 1995-05-18
US5420109A (en) 1995-05-30
KR100248033B1 (ko) 2000-04-01
JPH08508299A (ja) 1996-09-03
CA2153584C (en) 2000-05-09

Similar Documents

Publication Publication Date Title
FI953378A0 (fi) Sytokiiniä pidättävät aineet
CA2189250A1 (en) Cytokine regulatory agents and methods of use in pathologies and conditions associated with altered cytokine levels
ES2149276T3 (es) Imidazo(4,5-c)piridin-4-aminas.
DE69124274D1 (de) Oligopeptide, sie enthaltende pharmazeutische und Futterzusammensetzung und Benützung von Oligopeptiden
DK0693924T3 (da) Fremgangsmåde til (in vivo)-levering af biologiske materialer og sammensætninger, der er egnede dertil
DE1019040T1 (de) Hemmung von p38 kinase aktivität durch arylharnstoff
PT735818E (pt) Proteinas inflamatorias de macrofagos pim-3 pim-4 e pim-1y
NO954722D0 (no) Peptid inhibitorer med urokinase reseptoraktivitet
DE69422169D1 (de) Modifizierte proteine und peptide enthaltende pharmazeutische mittel
DE69331739D1 (de) Neuartige pharmazeutische verwendungen von krill-enzymen
FR2694296B1 (fr) Peptides inhibant l'activité des protéines ras, préparation et utilisation.
MX9204240A (es) Montaje distribuidor y de mezclado de dos etapas para preparaciones tal como cementos dentales.
BR0312889A (pt) Polipeptìdeo t20 peguilado
ATE67783T1 (de) Homogene rekombinante immun-interferon-fragmente und diese enthaltende pharmazeutische zusammensetzungen.
DK0719276T3 (da) Ïstradiolestre med stærk oral virkning samt farmaceutiske præparater med indhold deraf
IL106591A0 (en) An interferon alpha/beta binding protein,its preparation and pharmaceutical compositions containing it
DE69626050D1 (de) Pharmazeutische zusammensetzung enthaltend interferon-gamma stimulatoren
FI960839A0 (fi) Uusia tripeptidejä, jotka ovat käyttökelpoisia immuuni- ja CNS-terapiassa
ATE111920T1 (de) Lymphokine, dns-sequenzen, die diese lymphokine kodieren, und sie enthaltende pharmazeutische zusammensetzungen.
DE69836226D1 (de) Ifn rezeptor 1 bindende proteine, dafür kodierende dna und verfahren zur regulierung der zellulären antwort auf interferone
NO905375L (no) Fremg. og preparater for behandling av pattedyr-infeksjoner under anv. av medikamenter som omfatter hymenoptera venom, protein- eller polypepti-komponenter derav, eller analoger av slike protein- eller polypeptid-komponenter.
ITMI931417A0 (it) Composizioni farmaceutiche e/o dermocosmetologiche e cosmetiche contenenti colostro equino
MX9604539A (es) Aminoacidos modificados para la distribucion de farmaco.
ITMI932544A0 (it) Composizioni farmaceutiche e/o dermocosmetologiche e cosmetiche contenenti colostro bovino.
AU3975693A (en) Recombinant active forms of ECEF, proteins that associate therewith, and uses thereof

Legal Events

Date Code Title Description
GB Transfer or assigment of application

Owner name: TREGA BIOSCIENCES, INC.